Compounded Semaglutide vs Tirzepatide
A side-by-side research comparison of Compounded Semaglutide and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Compounded Semaglutide | Tirzepatide |
|---|---|---|
| Full name | Compounded Semaglutide (503B Pharmacy) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | FDA Approved |
| Mechanism | Identical to branded semaglutide - a GLP-1 receptor agonist with a fatty acid chain for albumin binding, providing extended half-life. Reduces appetite, slows gastric emptying, and improves insulin sensitivity. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 4113.58 Da | 4,814 Da |
| Half-life | ~7 days | 5 days (120 hours) |
| Bioavailability | ~89% subcutaneous | High (SubQ ~80%) |
| Typical dose | 0.25-2.4 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Compounded Semaglutide reported benefits
- Significant weight loss (15-20%)
- Appetite suppression
- Improved glycemic control
- Cardiovascular benefits
- Reduced food noise
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.